Corbus Pharmaceuticals Holdings Inc CRBP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:23 PM EDT
42.50quote price arrow up+2.73 (+6.86%)
Volume
655,434
52 week range
3.03 - 49.87
Loading...
  • Open39.99
  • Day High44.66
  • Day Low39.31
  • Prev Close39.77
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap446.558M
  • Shares Out10.51M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta2.52
  • YTD % Change581.79

KEY STATS

  • Open39.99
  • Day High44.66
  • Day Low39.31
  • Prev Close39.77
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23
  • Market Cap446.558M
  • Shares Out10.51M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta2.52
  • YTD % Change581.79

RATIOS/PROFITABILITY

  • EPS (TTM)-10.38
  • P/E (TTM)-4.09
  • Fwd P/E (NTM)-6.97
  • EBITDA (TTM)-44.436M
  • ROE (TTM)-341.98%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-36,090.23%
  • Debt To Equity (MRQ)-234.75%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Corbus Pharmaceuticals Holdings Inc

 

Profile

MORE
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913...
Alan Holmer J.D.
Independent Chairman of the Board
Yuval Cohen Ph.D.
Chief Executive Officer, Director
Sean Moran CPA
Chief Financial Officer
Address
500 River Ridge Drive
Norwood, MA
02062
United States

Top Peers

SYMBOLLASTCHG%CHG
TRML
Tourmaline Bio Inc
15.62-0.16-1.01%
AURA
Aura Biosciences Inc
7.36-0.13-1.74%
REPL
Replimune Group Inc
6.68-0.20-2.91%
SLRN
ACELYRIN Inc
4.75+0.13+2.92%
PLSE
Pulse Biosciences Inc
7.03-0.57-7.50%